Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seventh Statin Appoved: Kowa Will Take A Niche Strategy For Livalo

Executive Summary

Kowa's decision to emphasize its newly approved statin Livalo'seffect in populations that are hard to treat with other statins is a wise strategy for a late entry to a class dominated by popular generics and well-established brands from marketing powerhouses like Pfizer and AstraZeneca
Advertisement

Related Content

Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
Lilly Puts On A Happy Face, But Will Investors Buy In?
Lilly Puts On A Happy Face, But Will Investors Buy In?
Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
Biologics Reached Record Share Of Novel Approvals In 2009
Biologics Reached Record Share Of Novel Approvals In 2009
Biologics Reached Record Share Of Novel Approvals In 2009
Novartis To Seek Licensing Partner For Pitavastatin

Topics

Advertisement
UsernamePublicRestriction

Register

PS051367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel